148 related articles for article (PubMed ID: 31427704)
1. Evaluation of antigenic differences between wild and Sabin vaccine strains of poliovirus using the pseudovirus neutralization test.
Arita M; Iwai-Itamochi M
Sci Rep; 2019 Aug; 9(1):11970. PubMed ID: 31427704
[TBL] [Abstract][Full Text] [Related]
2. High-throughput analysis of anti-poliovirus neutralization antibody titre in human serum by the pseudovirus neutralization test.
Arita M; Iwai-Itamochi M
Sci Rep; 2022 Sep; 12(1):16074. PubMed ID: 36167892
[TBL] [Abstract][Full Text] [Related]
3. Differences in Antigenic Structure of Inactivated Polio Vaccines Made From Sabin Live-Attenuated and Wild-Type Poliovirus Strains: Impact on Vaccine Potency Assays.
Crawt L; Atkinson E; Tedcastle A; Pegg E; ; Minor P; Cooper G; Rigsby P; Martin J
J Infect Dis; 2020 Feb; 221(4):544-552. PubMed ID: 30788503
[TBL] [Abstract][Full Text] [Related]
4. Determination of antigenic properties of vaccine derived poliovirus strains.
Pliaka V; Achilleos C; Kyriakopoulou Z; Tsakogiannis D; Ruether IG; Gartzonica C; Levidiotou-Stefanou S; Markoulatos P
Vaccine; 2010 Dec; 29(1):26-33. PubMed ID: 20974307
[TBL] [Abstract][Full Text] [Related]
5. Dynamics of Evolution of Poliovirus Neutralizing Antigenic Sites and Other Capsid Functional Domains during a Large and Prolonged Outbreak.
Shaw J; Jorba J; Zhao K; Iber J; Chen Q; Adu F; Adeniji A; Bukbuk D; Baba M; Henderson E; Dybdahl-Sissoko N; McDonald S; Weldon WC; Gumede N; Oberste MS; Kew OM; Burns CC
J Virol; 2018 May; 92(9):. PubMed ID: 29444940
[TBL] [Abstract][Full Text] [Related]
6. A safe and reliable neutralization assay based on pseudovirus to measure neutralizing antibody titer against poliovirus.
Liu S; Song D; Bai H; Lu W; Dai X; Hao C; Zhang Z; Guo H; Zhang Y; Li X
J Med Virol; 2017 Dec; 89(12):2075-2083. PubMed ID: 28786502
[TBL] [Abstract][Full Text] [Related]
7. Characterization of human monoclonal antibodies that neutralize multiple poliovirus serotypes.
Puligedda RD; Kouiavskaia D; Al-Saleem FH; Kattala CD; Nabi U; Yaqoob H; Bhagavathula VS; Sharma R; Chumakov K; Dessain SK
Vaccine; 2017 Oct; 35(41):5455-5462. PubMed ID: 28343771
[TBL] [Abstract][Full Text] [Related]
8. Isolation of an intertypic poliovirus capsid recombinant from a child with vaccine-associated paralytic poliomyelitis.
Martín J; Samoilovich E; Dunn G; Lackenby A; Feldman E; Heath A; Svirchevskaya E; Cooper G; Yermalovich M; Minor PD
J Virol; 2002 Nov; 76(21):10921-8. PubMed ID: 12368335
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a recombinant type 3/type 2 poliovirus isolated from a healthy vaccinee and containing a chimeric capsid protein VP1.
Blomqvist S; Bruu AL; Stenvik M; Hovi T
J Gen Virol; 2003 Mar; 84(Pt 3):573-580. PubMed ID: 12604808
[TBL] [Abstract][Full Text] [Related]
10. Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains.
Kersten G; Hazendonk T; Beuvery C
Vaccine; 1999 Apr; 17(15-16):2059-66. PubMed ID: 10217607
[TBL] [Abstract][Full Text] [Related]
11. A recombinant virus between the Sabin 1 and Sabin 3 vaccine strains of poliovirus as a possible candidate for a new type 3 poliovirus live vaccine strain.
Kohara M; Abe S; Komatsu T; Tago K; Arita M; Nomoto A
J Virol; 1988 Aug; 62(8):2828-35. PubMed ID: 2839704
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the neutralizing activities of antibodies in clinical sera against both Sabin and wild-type polio pseudoviruses.
Liu S; Lu W; Ma S; Guo H; Zhang Z; Li X
J Virol Methods; 2022 Feb; 300():114376. PubMed ID: 34826519
[TBL] [Abstract][Full Text] [Related]
13. A simple and safe antibody neutralization assay based on polio pseudoviruses.
Jiang Z; Liu G; Guo-Yang L; Sun M; Xu K; Ying Z; Wang J; Li X; Li C
Hum Vaccin Immunother; 2019; 15(2):349-357. PubMed ID: 30273512
[TBL] [Abstract][Full Text] [Related]
14. Rapid and accurate identification of poliovirus strains used for vaccine production.
Nijst OE; Mouthaan JJ; Mekkes DR; Jusic E; van der Avoort HG; Metz B
J Virol Methods; 2013 Apr; 189(1):189-95. PubMed ID: 23434540
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy.
Dragunsky EM; Ivanov AP; Wells VR; Ivshina AV; Rezapkin GV; Abe S; Potapova SG; Enterline JC; Hashizume S; Chumakov KM
J Infect Dis; 2004 Oct; 190(8):1404-12. PubMed ID: 15378432
[TBL] [Abstract][Full Text] [Related]
16. Differentiation of poliovirus type I isolates in the 1982 epidemic from Sabin-I strain by antigenic and temperature markers.
Lee CN; Kao CL; Lee CY
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1987 Feb; 20(1):80-8. PubMed ID: 3036431
[TBL] [Abstract][Full Text] [Related]
17. Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccines.
Westdijk J; Brugmans D; Martin J; van't Oever A; Bakker WA; Levels L; Kersten G
Vaccine; 2011 Apr; 29(18):3390-7. PubMed ID: 21397718
[TBL] [Abstract][Full Text] [Related]
18. Development of a poliovirus neutralization test with poliovirus pseudovirus for measurement of neutralizing antibody titer in human serum.
Arita M; Iwai M; Wakita T; Shimizu H
Clin Vaccine Immunol; 2011 Nov; 18(11):1889-94. PubMed ID: 21880850
[TBL] [Abstract][Full Text] [Related]
19. Immunological and pathogenic properties of poliovirus variants selected for resistance to antiviral drug V-073.
Kouiavskaia DV; Dragunsky EM; Liu HM; Oberste MS; Collett MS; Chumakov KM
Antivir Ther; 2011; 16(7):999-1004. PubMed ID: 22024515
[TBL] [Abstract][Full Text] [Related]
20. Robustness against serum neutralization of a poliovirus type 1 from a lethal epidemic of poliomyelitis in the Republic of Congo in 2010.
Drexler JF; Grard G; Lukashev AN; Kozlovskaya LI; Böttcher S; Uslu G; Reimerink J; Gmyl AP; Taty-Taty R; Lekana-Douki SE; Nkoghe D; Eis-Hübinger AM; Diedrich S; Koopmans M; Leroy EM; Drosten C
Proc Natl Acad Sci U S A; 2014 Sep; 111(35):12889-94. PubMed ID: 25136105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
